Genetic association study of individual symptoms in depression

Psychiatry Research

Volumn 198, Issue 3, 2012, Pages 400-406

  Myung, Woojae ^a   Song, Jihye ^a   Lim, Shinn Won ^b   Won, Hong Hee ^b   Kim, Seonwoo ^b   Lee, Yujin ^a   Kang, Hyo Shin ^b   Lee, Hong ^b   Kim, Jong Won ^a   Carroll, Bernard J ^c   Kim, Doh Kwan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Pacific Behavioral Research Foundation   (United States)

Author keywords

Anxiety; Depression; Genetics; Guilt; Insomnia

Indexed keywords

ALANINE; ANTIDEPRESSANT AGENT; CYSTEINE; FLUOXETINE; GLYCINE; IONOTROPIC RECEPTOR; MILNACIPRAN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; TRYPTOPHAN HYDROXYLASE; VENLAFAXINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; ETHNIC GROUP; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRIA3 GENE; GRIK2 GENE; GUILT; HAPLOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TPH1 GENE; TREATMENT DURATION;

AGED; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC ASSOCIATION STUDIES; GUILT; HAPLOTYPES; HUMANS; INDIVIDUALITY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; SYMPTOM ASSESSMENT; TRYPTOPHAN HYDROXYLASE;

EID: 84868632690     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.12.037     Document Type: Article

References (62)

1. Adrien J. Neurobiological bases for the relation between sleep and depression. Sleep Medicine Reviews 2002, 6:341-351.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, (Text Revision), American Psychiatric Association, Washington, DC. 4th ed.
3. Amin A.H., Crawford T.B., Gaddum J.H. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. Journal of Physiology (London) 1954, 126:596-618.
4. Balding D.J. A tutorial on statistical methods for population association studies. Nature Reviews Genetics 2006, 7:781-791.
5. Barbon A., Popoli M., La Via L., Moraschi S., Vallini I., Tardito D., Tiraboschi E., Musazzi L., Giambelli R., Gennarelli M., Racagni G., Barlati S. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biological Psychiatry 2006, 59:713-720.
6. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
7. Basile B., Mancini F., Macaluso E., Caltagirone C., Frackowiak R.S., Bozzali M. Deontological and altruistic guilt: evidence for distinct neurobiological substrates. Human Brain Mapping 2011, 32:229-239.
8. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
9. Clayton P.J., Grove W.M., Coryell W., Keller M., Hirschfeld R., Fawcett J. Follow-up and family study of anxious depression. The American Journal of Psychiatry 1991, 148:1512-1517.
10. Dick D.M., Foroud T., Flury L., Bowman E.S., Miller M.J., Rau N.L., Moe P.R., Samavedy N., El-Mallakh R., Manji H., Glitz D.A., Meyer E.T., Smiley C., Hahn R., Widmark C., McKinney R., Sutton L., Ballas C., Grice D., Berrettini W., Byerley W., Coryell W., DePaulo R., MacKinnon D.F., Gershon E.S., Kelsoe J.R., McMahon F.J., McInnis M., Murphy D.L., Reich T., Scheftner W., Nurnberger J.I. Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. American Journal of Human Genetics 2003, 73:107-114.
11. Du L., Bakish D., Hrdina P.D. Tryptophan hydroxylase gene 218A/C polymorphism is associated with somatic anxiety in major depressive disorder. Journal of Affective Disorders 2001, 65:37-44.
12. Fava M., Uebelacker L.A., Alpert J.E., Nierenberg A.A., Pava J.A., Rosenbaum J.F. Major depressive subtypes and treatment response. Biological Psychiatry 1997, 42:568-576.
13. Fava M., Rush A.J., Alpert J.E., Balasubramani G.K., Wisniewski S.R., Carmin C.N., Biggs M.M., Zisook S., Leuchter A., Howland R., Warden D., Trivedi M.H. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. The American Journal of Psychiatry 2008, 165:342-351.
14. Flint A.J., Rifat S.L. Anxious depression in elderly patients. Response to antidepressant treatment. The American Journal of Geriatric Psychiatry 1997, 5:107-115.
15. Guzman-Marin R., Alam M.N., Szymusiak R., Drucker-Colin R., Gong H., McGinty D. Discharge modulation of rat dorsal raphe neurons during sleep and waking: effects of preoptic/basal forebrain warming. Brain Research 2000, 875:23-34.
16. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
17. Hamilton M. Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychology 1967, 6:278-296.
18. Hamilton M. Frequency of symptoms in melancholia (depressive illness). The British Journal of Psychiatry 1989, 154:201-206.
19. Hamon M., Bourgoin S., Artaud F., Nelson D. Regulatory properties of neuronal tryptophan hydroxylase. Advances in Experimental Medicine and Biology 1981, 133:231-251.
20. Holliday K.L., Macfarlane G.J., Nicholl B.I., Creed F., Thomson W., McBeth J. Genetic variation in neuroendocrine genes associates with somatic symptoms in the general population: results from the EPIFUND study. Journal of Psychosomatic Research 2010, 68:469-474.
21. Ioannidis J.P.A. Why most published research findings are false. PLoS Medicine 2005, 2:e124.
22. Jang K.L., Livesley W.J., Taylor S., Stein M.B., Moon E.C. Heritability of individual depressive symptoms. Journal of Affective Disorders 2004, 80:125-133.
23. Johnstone T., van Reekum C.M., Urry H.L., Kalin N.H., Davidson R.J. Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. Journal of Neuroscience 2007, 27:8877-8884.
24. Kim D.K., Lim S.W., Lee S., Sohn S.E., Kim S., Hahn C.G., Carroll B.J. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000, 11:215-219.
25. Kim H., Lim S.W., Kim S., Kim J.W., Chang Y.H., Carroll B.J., Kim D.K. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. Journal of the American Medical Association 2006, 296:1609-1618.
26. Kohli M.A., Salyakina D., Pfennig A., Lucae S., Horstmann S., Menke A., Kloiber S., Hennings J., Bradley B.B., Ressler K.J., Uhr M., Muller-Myhsok B., Holsboer F., Binder E.B. Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Archives of General Psychiatry 2010, 67:348-359.
27. Korszun A., Moskvina V., Brewster S., Craddock N., Ferrero F., Gill M., Jones I.R., Jones L.A., Maier W., Mors O., Owen M.J., Preisig M., Reich T., Rietschel M., Farmer A., McGuffin P. Familiality of symptom dimensions in depression. Archives of General Psychiatry 2004, 61:468-474.
28. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 2002, 7(Suppl. 1):S71-S80.
29. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrums 2005, 10:808-819.
30. Lachin J.M. Sample size determination for r×c comparative trials. Biometrics 1997, 33(315-324):1997.
31. Laje G., Allen A.S., Akula N., Manji H., John Rush A., McMahon F.J. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenetics and Genomics 2009, 19:666-674.
32. Lee H.J., Cha J.H., Ham B.J., Han C.S., Kim Y.K., Lee S.H., Ryu S.H., Kang R.H., Choi M.J., Lee M.S. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. The Pharmacogenomics Journal 2004, 4:29-33.
33. Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Zarate C.A. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Current Pharmaceutical Design 2009, 15:1595-1611.
34. Malhotra A.K. The pharmacogenetics of depression: enter the GWAS. The American Journal of Psychiatry 2010, 167:493-495.
35. Martinez-Turrillas R., Frechilla D., Del Rio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 2002, 43:1230-1237.
36. Morin L.P. Serotonin and the regulation of mammalian circadian rhythmicity. Annals of Medicine 1999, 31:12-33.
37. Olson J.M., Foley M. Testing for homogeneity of Hardy-Weinberg disequilibrium using data sampled from several populations. Biometrics 1996, 52:971-979.
38. Patel P.D., Pontrello C., Burke S. Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biological Psychiatry 2004, 55:428-433.
39. Pralong E., Magistretti P., Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Progress in Neurobiology 2002, 67:173-202.
40. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 2007, 81:559-575.
41. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., Bhandari R., Rose M., Ivey J., Boyd C., Moore G.J. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43:1146-1153.
42. Sanacora G., Rothman D.L., Mason G., Krystal J.H. Clinical studies implementing glutamate neurotransmission in mood disorders. Annals of the New York Academy of Sciences 2003, 1003:292-308.
43. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2011, 62:63-77.
44. Schaid D.J., Jacobsen S.J. Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. American Journal of Epidemiology 1999, 149:706-711.
45. Schulze T.G., Buervenich S., Badner J.A., Steele C.J., Detera-Wadleigh S.D., Dick D., Foroud T., Cox N.J., MacKinnon D.F., Potash J.B., Berrettini W.H., Byerley W., Coryell W., DePaulo J.R., Gershon E.S., Kelsoe J.R., McInnis M.G., Murphy D.L., Reich T., Scheftner W., Nurnberger J.I., McMahon F.J. Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the National Institute of Mental Health genetics initiative pedigrees. Biological Psychiatry 2004, 56:18-23.
46. Shin L.M., Dougherty D.D., Orr S.P., Pitman R.K., Lasko M., Macklin M.L., Alpert N.M., Fischman A.J., Rauch S.L. Activation of anterior paralimbic structures during guilt-related script-driven imagery. Biological Psychiatry 2000, 48:43-50.
47. Skolnick P. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids 2002, 23:153-159.
48. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., Boutin P., Vincent D., Belisle A., Hadjadj S., Balkau B., Heude B., Charpentier G., Hudson T.J., Montpetit A., Pshezhetsky A.V., Prentki M., Posner B.I., Balding D.J., Meyre D., Polychronakos C., Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
49. Stephens M., Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. American Journal of Human Genetics 2003, 73:1162-1169.
50. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences 2003, 100:9440-9445.
51. Tanti A., Belzung C. Open questions in current models of antidepressant action. British Journal of Pharmacology 2010, 159:1187-1200.
52. Trulson M.E., Jacobs B.L. Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Research 1979, 163:135-150.
53. Tsai S.J., Cheng C.Y., Yu Y.W., Chen T.J., Hong C.J. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2003, 123B:19-22.
54. Tsai S.J., Hong C.J., Liu M.E., Hou S.J., Yen F.C., Hsieh C.H., Liou Y.J. Interleukin-1 beta (C-511T) genetic polymorphism is associated with cognitive performance in elderly males without dementia. Neurobiology of Aging 2010, 31:1950-1955.
55. Ursin R. Serotonin and sleep. Sleep Medicine Reviews 2002, 6:55-69.
56. Walther D.J., Bader M. A unique central tryptophan hydroxylase isoform. Biochemical Pharmacology 2003, 66:1673-1680.
57. Wang N., Akey J.M., Zhang K., Chakraborty R., Jin L. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. American Journal of Human Genetics 2002, 71:1227-1234.
58. Williams J.B. A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry 1988, 45:742-747.
59. Wong M.L., Licinio J. Research and treatment approaches to depression. Nature Reviews Neuroscience 2001, 2:343-351.
60. Wu Y., Arai A.C., Rumbaugh G., Srivastava A.K., Turner G., Hayashi T., Suzuki E., Jiang Y., Zhang L., Rodriguez J., Boyle J., Tarpey P., Raymond F.L., Nevelsteen J., Froyen G., Stratton M., Futreal A., Gecz J., Stevenson R., Schwartz C.E., Valle D., Huganir R.L., Wang T. Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:18163-18168.
61. Yu Y.W., Tsai S.J., Chen T.J., Lin C.H., Hong C.J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular Psychiatry 2002, 7:1115-1119.
62. Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.